Exploring the Genomes of Cancer Cells: Progress and Promise

By Michael R. Stratton. Science, 2011

707 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/89664d5e6b4b3fea7bc83133aff26159511104f2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

In Pulmonary and Respiratory Medicine

Citations in the corpus

A compendium of mutational cancer driver genes (2020, methodology): “Literature (2,257;8) Hartwig (3,742;30) Multiple myeloma (1,122;3)”
Deciphering Signatures of Mutational Processes Operative in Human Cancer (2013, positive): “…of simulated cancer genomes whereas the total number of mutations ineachmutational catalog wasdrawn from adistribution comparable to the distribution of the total substitutions found in many human cancer genomes (Greenman et al., 2007; Nik-Zainal et al., 2012a; Stratton, 2011; Wood et al., 2007).”
Infrared spectroscopy and microscopy in cancer research and diagnosis. (2012, background): “Cancer is a multi-step process resulting from the accumulation of irreversible and transmittable genetic aberrations together with the concurrent presence of epigenetic alterations in susceptible cells [1, 2].”
Mutational Processes Molding the Genomes of 21 Breast Cancers (2012, background): “A small proportion are ‘‘drivers’’ that confer clonal advantage, are causally implicated in oncogenesis, and have been positively selected during the evolution of the cancer (Stratton, 2011; Stratton et al., 2009).”
Exploiting the mutanome for tumor vaccination. (2012, background): “The advent of next generation sequencing (NGS) technology has added a new dimension to genome research by generating ultrafast and high-throughput sequencing data in an unprecedented manner (1).”
Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer (2015, background): “Several approaches have been proposed, including application of gene expression profiles of BRCAness (48) or DNA repair (49), evaluating BRCA1 protein expression by immunohistochemistry (50), and assessing the wider tumor genome nucleotide sequences and mutational spectrums, or “sequence scars,” tha”
VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. (2012, background): “…of tumor samples and matched normal controls has the potential to rapidly identify protein-altering mutations across hundreds of patients, potentially enabling the discovery of recurrent events driving tumor development and growth (International Cancer Genome Consortium 2010; Stratton 2011).”
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells (2012, background): “Recent years have seen signiﬁcant advances in our understanding of the molecular nature of cancer (4).”